Can I Get Pluvicto Before Chemotherapy for Advanced Prostate Cancer?

October 13, 2026

Pluvicto may be an option before taxane chemotherapy for adults with PSMA-positive metastatic castration-resistant prostate cancer who have already received an androgen receptor pathway inhibitor and are considered appropriate to delay chemotherapy. The March 2025 FDA expansion does not apply to hormone-sensitive prostate cancer, and eligibility depends on PSMA PET findings, prior treatment, disease status, and an oncology team's assessment.

The apparent paradox is simple: a treatment can be used before chemotherapy without being a general substitute for chemotherapy. The distinction is doing nearly all of the work here. Pluvicto's expanded U.S. indication is narrow, evidence-based, and tied to a particular disease state rather than to the broad phrase “advanced prostate cancer.”

Can I get Pluvicto before chemotherapy?

Yes, but only if the clinical facts fit the March 2025 FDA indication: PSMA-positive metastatic castration-resistant prostate cancer, prior treatment with an androgen receptor pathway inhibitor (ARPI), and a determination that delaying taxane-based chemotherapy is appropriate. “Metastatic” means the cancer has spread; “castration-resistant” means it has progressed despite treatment intended to lower or block testosterone's effect. Those are not interchangeable labels.

According to the U.S. Food and Drug Administration's March 2025 announcement, the expansion followed the PSMAfore study in patients whose cancer had progressed after an ARPI. The FDA reported that radiographic progression-free survival, meaning the time until imaging showed progression or death, was 9.3 months with Pluvicto and 5.6 months after a change in ARPI therapy in its 2025 review.

That comparison matters. PSMAfore did not compare Pluvicto directly with taxane chemotherapy. The 2024 Lancet report of the PSMAfore phase 3 trial compared Pluvicto with switching to abiraterone or enzalutamide after prior ARPI treatment. It supports a specific conclusion: for eligible patients being considered for another ARPI, Pluvicto can be a treatment alternative before taxane chemotherapy. It does not answer which treatment is superior to chemotherapy for an individual patient.

Question	What the evidence establishes
Can Pluvicto be considered before taxane chemotherapy?	Yes, for the FDA-defined group with PSMA-positive mCRPC, prior ARPI treatment, and clinical appropriateness to delay taxane chemotherapy.
Was Pluvicto tested directly against chemotherapy in PSMAfore?	No. The comparator was a change to another ARPI.
Does the expanded indication cover every advanced prostate cancer?	No. The FDA indication is for PSMA-positive metastatic castration-resistant prostate cancer.

What PSMA PET scan result do I need to qualify for Pluvicto?

A qualifying result requires PSMA-positive tumor expression on an approved PSMA PET product, but the scan is not a simple yes-or-no blood test. The 2025 FDA prescribing information directs clinicians to select patients using Locametz or another approved PSMA PET product based on PSMA expression in tumors.

The trial rule gives the concept more precision. In PSMAfore, the FDA's 2025 prescribing information describes eligibility as having at least one tumor lesion with gallium-68 gozetotide uptake greater than normal liver, while certain larger lesions with uptake at or below normal liver made a patient ineligible. In plain language: enough tumor needs to show the target, and clinically significant sites cannot show a pattern suggesting the radioligand would miss them.

This is why a scan result should be read as a treatment-selection tool, not a verdict delivered in isolation. The ClinicalTrials.gov record for PSMAfore confirms that participants underwent gallium-68 PSMA-11 PET/CT screening before randomization. The scan identifies target expression; the cancer's treatment history and a patient's overall clinical situation determine whether that result becomes an approved treatment option.

Is Pluvicto used for castration-resistant or hormone-sensitive prostate cancer?

Pluvicto's March 2025 U.S. indication discussed here is for castration-resistant prostate cancer, specifically PSMA-positive metastatic castration-resistant prostate cancer, not hormone-sensitive prostate cancer. The prior-treatment requirement is equally consequential: patients in this indication have already received an ARPI.

The term “castration-resistant” can sound like a description of severity alone. It is more exact than that: it identifies the setting in which the cancer has progressed despite ongoing testosterone-lowering treatment. The FDA label also covers patients who have already received taxane chemotherapy, but the 2025 expansion created the earlier-use pathway for patients appropriate to delay it. The stage, the prior medicines, and the PET result form a chain; breaking any link changes the discussion.

Questions to bring to the oncology visit

A productive appointment does not require a patient or caregiver to decide between treatments in the room. It requires separating the questions that are often bundled together:

Does the current diagnosis meet the FDA definition of PSMA-positive metastatic castration-resistant prostate cancer?
Has prior ARPI treatment been documented, and has the cancer progressed after it?
Which approved PSMA PET product will be used, and how will the scan be interpreted against the trial-based criteria?
What is the clinical reason to delay, begin, or reconsider taxane chemotherapy in this case?
Which blood counts, kidney-function results, imaging findings, and symptoms will be followed during treatment?
What result would lead the team to continue, pause, or change the treatment plan?

These questions force the decision into its actual components: target expression, prior therapy, disease behavior, safety monitoring, and treatment goals. That is more useful than asking whether Pluvicto is simply “better” than chemotherapy, because the evidence does not support such a universal claim.

Frequently Asked Questions

How does Pluvicto compare with chemotherapy for advanced prostate cancer?

The available PSMAfore evidence does not directly compare Pluvicto with chemotherapy. The phase 3 trial compared Pluvicto with a switch to another androgen receptor pathway inhibitor in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer. The FDA's March 2025 indication therefore frames Pluvicto as an option for eligible patients considered appropriate to delay taxane chemotherapy, not as a proven replacement for chemotherapy in every situation.

What side effects should patients expect during Pluvicto treatment?

The 2025 FDA prescribing information lists blood-count changes, fatigue, dry mouth, kidney-function changes, and nausea among common adverse reactions observed across its safety population. Laboratory monitoring, including complete blood counts and kidney-function tests, is part of treatment safety monitoring. The practical question is not whether side effects exist; it is whether a patient's baseline health, laboratory results, symptoms, and treatment goals make the trade-off acceptable.

How often are Pluvicto treatments given and how is response monitored?

The 2025 FDA prescribing information sets the approved treatment regimen, while the treating oncology and nuclear medicine teams determine how it applies to an individual patient and whether treatment should continue. In the PSMAfore trial, imaging was scheduled at regular intervals to look for radiographic progression, and blood counts and kidney function were monitored for safety. A treatment visit is therefore part administration, part surveillance: response and tolerability are evaluated together.

Sources

Disclaimer: This article is for general information only and is not medical advice. It is not a substitute for diagnosis or treatment by a qualified healthcare professional. Always speak to your doctor before acting on anything you read here.